Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Stopped \< 75 % participation
Conditions
- Advanced Malignant Neoplasm
- Castleman Disease
- Digestive System Carcinoma
- Erdheim-Chester Disease
- Lip and Oral Cavity Carcinoma
- Lymphangioleiomyomatosis
- Malignant Endocrine Neoplasm
- Malignant Female Reproductive System Neoplasm
- Malignant Male Reproductive System Neoplasm
- Malignant Neoplasm
- Malignant Respiratory Tract Neoplasm
- Malignant Thoracic Neoplasm
- Malignant Urinary System Neoplasm
- Mesothelial Neoplasm
- Metastatic Malignant Neoplasm
- Metastatic Urothelial Carcinoma
- Neurofibromatosis Type 2
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Breast Carcinoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Digestive System Carcinoma
- Recurrent Female Reproductive System Carcinoma
- Recurrent Male Reproductive System Carcinoma
- Recurrent Malignant Neoplasm
- Recurrent Pharyngeal Carcinoma
- Recurrent Thyroid Gland Carcinoma
- Refractory Malignant Neoplasm
- Soft Tissue Neoplasm
- Stage III Breast Cancer AJCC v7
- Stage III Pharyngeal Cancer
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Pharyngeal Cancer
- Stage IVA Pharyngeal Cancer
- Stage IVB Pharyngeal Cancer
- Stage IVC Pharyngeal Cancer
- Thyroid Gland Neoplasm
Interventions
- BIOLOGICAL: Bevacizumab
- BIOLOGICAL: Cetuximab
- OTHER: Laboratory Biomarker Analysis
- OTHER: Pharmacological Study
- DRUG: Temsirolimus
- DRUG: Valproic Acid
Sponsor
M.D. Anderson Cancer Center
Collaborators